Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
The binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) on the surface of tumor cells is involved in the activation of proteolytic cascades responsible for the invasiveness of those cells. The diffuse, extensive infiltration of glioblastomas into the surrounding normal brain tissue is believed to rely on modifications of the proteolysis of extracellular matrix components; blocking the interaction between uPA and uPAR might be a suitable approach for inhibiting glioma tumorigenesis. We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells. SNB19 cells were transfected with an expression plasmid (pcDNA3-ATF) containing a cDNA sequence of ATF-uPA. The resulting ATF-uPA-expressing clones showed markedly less cell adhesion, spreading, and clonogenicity than did control cells. Endogenous ATF expression also significantly decreased the invasive capacity of transfected glioblastoma cells in Matrigel and spheroid-rat brain cell aggregate models. ATF-uPA transfectants were also markedly less invasive than parental SNB19 cells after injection into the brains of nude mice, suggesting that competitive inhibition of the uPA-uPAR interaction on SNB19 cells by means of transfection with ATF cDNA could be a useful therapeutic strategy for inhibiting tumor progression.
Mohanam
Sanjeeva
S
Division of Cancer Biology, Department of Biomedical and Therapeutic Sciences, University of Illinois College of Medicine at Peoria, Peoria, Illinois 61656-1649, USA.
Chandrasekar
Nirmala
N
Yanamandra
Niranjan
N
Khawar
Siddique
S
Mirza
Faiz
F
Dinh
Dzung H
DH
Olivero
William C
WC
Rao
Jasti S
JS
D000199:Actins / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D001932:Brain Neoplasms / Q000201:enzymology / Q000473:pathology* / Q000628:therapy; D002448:Cell Adhesion; D002449:Cell Aggregation; D002999:Clone Cells / Q000473:pathology; D003094:Collagen; D003599:Cytoskeleton / Q000648:ultrastructure; D018076:DNA, Complementary / Q000235:genetics; D004338:Drug Combinations; D015316:Genetic Therapy; D005909:Glioblastoma / Q000201:enzymology / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007797:Laminin; D051379:Mice; D008819:Mice, Nude; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D009363:Neoplasm Proteins / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D017434:Protein Structure, Tertiary; D011509:Proteoglycans; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D011993:Recombinant Fusion Proteins / Q000502:physiology; D018874:Spheroids, Cellular / Q000473:pathology; D013329:Structure-Activity Relationship; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000473:pathology; D014410:Tumor Stem Cell Assay; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays
D000199:Actins; D018076:DNA, Complementary; D004338:Drug Combinations; D007797:Laminin; D009363:Neoplasm Proteins; C524898:PLAUR protein, human; C524899:Plaur protein, mouse; C524900:Plaur protein, rat; D011509:Proteoglycans; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D011993:Recombinant Fusion Proteins; C059485:matrigel; D003094:Collagen; D014568:Urokinase-Type Plasminogen Activator